About us
IDT Australia is a pharmaceutical manufacturer with five decades of experience in fast tracking the production of pharmaceuticals from the laboratory bench to the patient.
Since 1975, IDT Australia has brought expertise and innovation to local and international pharmaceutical projects with a full suite of contract manufacturing services.
Our mission is to improve and save lives through the development and reliable manufacture of effective and innovative pharmaceutical vaccines and treatments.
We specialize in high containment, high potency manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.
IDT Australia is also at the forefront of developing and manufacturing in the rapidly growing field of advanced therapies including mRNA and Antibody Drug Conjugates (ADCs). We are also specialists in manufacturing pharmaceuticals to treat mental health disorders including medicinal cannabis and we are now working on psychedelics.
We've been involved in developing more than 60 marketed drugs across our fifty-year history and we continue to innovate novel assets and build long-standing relationships with our partners.
OUR HISTORY
over 50 years of experience
1965
CONCEPTION
Dean of the Victorian College of Pharmacy Nigel Manning and his colleagues conceived an idea: to establish an institute of industrial pharmacy. This ambition was included in the Victorian College of Pharmacy Campus’ development strategy in 1970 and was realised five years later.
1975
ESTABLISHMENT
The Institute of Drug Technology Limited (IDT) was established as an independent company, and as an academic-industrial interface operating in conjunction with the Victorian College of Pharmacy Limited (VCP).
1975-1982
REPUTATION
IDT Australia established a reputation for providing high-quality contract and consultancy services. It relied on academic staff from the VCP as consultants and employed a small cohort of full- time scientists. Its mission was to further the drug and allied industries in Australia.
1982
CHAIRMAN APPOINTED
Dr Graeme Blackman, then a Senior Lecturer at the VCP was appointed Chairman and Executive Director and Professor of Pharmaceutical Chemistry. Under his guidance, the company continued to prosper and commenced a new phase of growth.
1988
TRANSITION
IDT transitioned from a private company to an unlisted public company. Shortly after, IDT Australia announced its acquisition of the Nicholas Kiwi Central Laboratories (NKCL).
1988
ASX LISTING
On February 12, 1988, IDT Australia was listed on the ASX, following the issue of approximately 24% of capital to public investors.